Observational Study of Biomarker During Liver Surgery

Stopped early

Conditions studied: Liver Cancer, Hepatobiliary Tract Adenomas and Carcinomas

In brief

The investigators would like to study whether Sirtuin 1 (SIRT1) plays a cytoprotective role in liver ischemia/reperfusion, and ultimately to develop therapeutic strategies to improve hepatic function of patients with liver diseases.

Key facts

Study ID

NCT02102971

Run by

University of Florida

People needed

41

Starts

2014-10-01

Expected to finish

2019-06-06

Last updated by the study team

2019-09-25

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• liver resection > 2 segments,
• plate count > 100 x 109/L, and
• prothrombin activity >60%.

You may not qualify if…

• liver cirrhosis,
• portal hypertension,
• steatohepatitis or severe steatosis,
• patients receiving additional ablation therapies,
• laparoscopic resection, and
• simultaneous extrahepatic procedures such as colorectal resection or pancreatoduodenectomy

Where it is running

• UF Health — Gainesville, Florida, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.